ReposiTrak® Enters Foodservice Channel, Taps Jorge Hernandez to Lead Advisory Board
Feb 10, 2016 13:30 pm UTC| Business
SALT LAKE CITY, Feb. 10, 2016 -- Park City Group’s (NASDAQ:PCYG) ReposiTrak®, the leading provider of Compliance Management and Track Trace solutions for retail food, pharma and dietary supplement safety, is expanding...
Sustainalytics’ ‘10 for 2016’ Report Presents Key Investor Insights Into the COP21 Agreement
Feb 10, 2016 13:30 pm UTC| Business
TORONTO, Feb. 10, 2016 -- Sustainalytics, a leading global provider of ESG and corporate governance research, ratings and analytics, today released a new thematic research report titled, 10 for 2016—The Paris Agreement:...
EHNAC Announces New Accreditation Program for Cloud-Enabled Service Providers
Feb 10, 2016 13:30 pm UTC| Business
FARMINGTON, Conn., Feb. 10, 2016 -- The Electronic Healthcare Network Accreditation Commission (EHNAC), a non-profit, federally recognized standards development organization and accrediting body for organizations that...
Geology and Finance Industry Veteran Joins Rostock Ventures Corp Board of Directors
Feb 10, 2016 13:30 pm UTC| Business
HENDERSON, Nev., Feb. 10, 2016 -- Rostock Ventures Corp. (OTCBB:ROSV) (the "Company") is pleased to announce that Eric Allison has joined the Company's Board of Directors. Mr. Allison has over 35 years of experience in...
3i-Infotech Executes One of Its Fastest Insurance Projects at Mitsui Sumitomo Insurance Company
Feb 10, 2016 13:10 pm UTC| Business
MUMBAI, India, Feb. 10, 2016 -- Mitsui Sumitomo Insurance Company (MSI) - Dubai, part of the largest conglomerate in the world, has selected 3i-Infotech's flagship Premia General Insurance product. Premia 11 is the...
Feb 10, 2016 13:05 pm UTC| Business
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin B) and MAT2501 (Encochleated Amikacin) - BEDMINSTER, N.J., Feb. 10, 2016 -- Matinas BioPharma...
Feb 10, 2016 13:00 pm UTC| Business
Once granted, the new U.S. patent covering methods of use forRHB-104 is expected to be valid through 2029RHB-104 is undergoing a first Phase III study for the treatment of Crohn’s disease in the U.S. and additional...